MAPT and Stroke: Compared to nimodipine alone, Tongxinluo combined with nimodipine significantly reduces serum levels of hs-CRP and Tau protein, increases IGF-1 levels, and improves neurological deficit symptoms in stroke patients, with no serious adverse reactions observed during the treatment period.